動脈硬化
Online ISSN : 2185-8284
Print ISSN : 0386-2682
ISSN-L : 0386-2682
糖尿病における中間体リポ蛋白蓄積の機序に関する検討
―リポ蛋白・レセプターの相互作用の障害の関与について―
焦 昇松沢 佑次野崎 秀一川本 俊治中村 正船橋 徹山下 静也藤岡 滋典中島 忠久上戸 寛亀田 芳久保 正治徳永 勝人垂井 清一郎
著者情報
ジャーナル オープンアクセス

1986 年 14 巻 3 号 p. 625-630

詳細
抄録
In order to assess the mechanism of accumulation of remnant lipoproteins in diabetes mellitus, we examined the lipoprotein metabolism in streptozotocin-induced diabetic rats. Cholesterol-fed diabetic rats showed a marked hyperlipoproteinemia associated with an elevation of chylomicrons and remnant lipoproteins. In VLDL fraction of the cholesterol-fed diabetic rats apolipoprotein E (apo E) was increased and apo A-I, which is absent from normal VLDL, was present. This might suggest the increase of chylomicron remnants in choles-terol-fed diabetics, indicating the impairment of exogenous cholesterol pathway in diabetes. When these animals were treated with a pharmacological dose of estrogen or triiodothyronine (T3), elevated remnants were cleared from plasma. Apo E was decreased in VLDL and HDL fractions by these treatments. We, furthermore, measured postheparin lipolytic activity. Lipoprotein lipase (LPL) activity was increased in cholesterol-fed diabetics, although hepatic lipase (HL) activity was not changed. When estrogen or T3 was injected to these rats, LPL and HL activities were suppressed. Therefore, the clearance of remnant lipoproteins by estrogen or T3 was not due to activition of lipolysis. The binding activity of hepatic lipoprotein receptor was also measured. The activity was enhanced by estrogen treatment in diabetics as well as in normal rats. However, there was no difference between the binding activity of hepatic receptor in diabetics and that in non-diabetics.
These data suggest that the chylomicron remnant accumulation was not due to inactivation of lipolysis. But we speculate at least in part an impaired interaction of remnant lipoproteins and hepatic receptor might contribute to the remnant lipoprotein accumulation.
著者関連情報
© 一般社団法人 日本動脈硬化学会

This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license.
https://creativecommons.org/licenses/by-nc-sa/4.0/
前の記事 次の記事
feedback
Top